Alkahest

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Alkahest sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 8 completed early-phase tilt top decile by trial count

Alkahest: 9 sponsored US clinical trials, none currently recruiting.

Alkahest sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Neovascular Age-related Macular Degeneration, with 1 trials.

Top-decile sponsor footprint

Alkahest ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

How the Alkahest early-phase archive is shaped

9 indexed studies, none listed as recruiting (0% open); 8 completed (89%).

Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Neovascular Age-related Macular Degeneration (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Alkahest: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Alkahest sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Alkahest4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
Alkahest sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Alkahest sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Alkahest page

9 registered trials is a research-attention snapshot, not an endorsement of Alkahest or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Alkahest pipeline card: 9 registered trials from official public datasets.Report a data error.